Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2- methoxy idazoxan) in the human and rat brains

A Miralles, G Olmos, M Sastre, F Barturen, I Martin and JA Garcia-Sevilla

Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Spain.

The alpha-2 adrenoceptor antagonist idazoxan has been shown to also recognize with high affinity nonadrenoceptor sites (I2-imidazoline sites). In contrast, the 2-methoxy derivative of idazoxan, 2-methoxy idazoxan (RX821002), binds almost exclusively to alpha-2 adrenoceptors. The purpose of this study was to assess and extend the pharmacological characterization of I2-imidazoline sites and alpha-2 adrenoceptors in the human and rat brains. Competition studies with several imidazoli(di)ne/guanidine drugs and other nonrelated structures were performed in cortical membranes against [3H]idazoxan (4 nM in the presence of 10(-6) M I-epinephrine to prevent binding to alpha-2 adrenoceptors) or [3H]RX821002 (1 nM). Drugs such as cirazoline, guanoxan, naphazoline, tolazoline, clonidine, bromoxidine (UK 14,304) and phenylbiguanide displaced [3H]idazoxan from two distinct binding sites, which suggested the existence of two affinity states for I2- imidazoline sites that were not modulated by MgCl2 or the nucleotide analog guanylyl-5'-imido-diphosphate. Binding affinities at the low- affinity site (KiL) were consistently more than 2 orders of magnitude lower than binding affinities at the high-affinity site (KiH), and there was a good correlation between KiH and KiL values for a given drug in the human (r = 0.89) and rat (r = 0.92) brains. For 18 to 22 drugs, the Ki values in the human brain correlated well with the corresponding Ki values in the rat brain both for I2-imidazoline sites (r = 0.94) and alpha-2 adrenoceptors (r = 0.97). However, the Ki values for I2-imidazoline sites did not correlate with the Ki values for alpha- 2 adrenoceptors in human and rat brains. The order of drug potency for the I2-imidazoline sites was: guanoxan (1.3 nM) approximately cirazoline > idazoxan approximately naphazoline > clonidine > phentolamine > RX821002 > (8aR, 12aS, 13aS)-3-methoxy-12- methanesulfonyl-5,6,8a,9,10,11,12,12a,13,13a- decahydro-8H-isoquino[2,1- g]-naphthyridine (RS 15385-197) (> 10 microM). In contrast, the potencies at the alpha-2 adrenoceptor were: RS 1538-197 (0.3 nM) > RX821002 > clonidine > phentolamine > idazoxan approximately naphazoline > guanoxan approximately cirazoline (307 nM). The results demonstrate that I2-imidazoline sites (labeled by [3H]idazoxan) and alpha-2 adrenoceptors are different pharmacological entities with similar characteristics in the human and rat brains. In both species, I2-imidazoline sites are markedly heterogeneous in nature.

Volume 264, Issue 3, pp. 1187-1197, 03/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. B. Bylund and D. M. Chacko Characterization of {alpha}2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2299 - 2306. [Abstract] [Full Text] [PDF]

				P. Chopin, F. C. Colpaert, and M. Marien Effects of Alpha-2 Adrenoceptor Agonists and Antagonists on Circling Behavior in Rats with Unilateral 6-Hydroxydopamine Lesions of the Nigrostriatal Pathway J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 798 - 804. [Abstract] [Full Text]

				G. J. Molderings, K. Donecker, M. Burian, W. A. Simon, D. W. Schröder, and M. Göthert Characterization of I2 Imidazoline and sigma  Binding Sites in the Rat and Human Stomach J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 170 - 177. [Abstract] [Full Text]

				J. A. Garcia-Sevilla, P. V. Escriba, M. Sastre, C. Walzer, X. Busquets, G. Jaquet, D. J. Reis, and J. Guimon Immunodetection and Quantitation of Imidazoline Receptor Proteins in Platelets of Patients With Major Depression and in Brains of Suicide Victims Arch Gen Psychiatry, September 1, 1996; 53(9): 803 - 810. [Abstract] [PDF]